DNA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
20.2M
+3.5%
19.5M
-41.7%
33.4M
-14.0%
38.8M
-0.8%
39.1M
Cost of Revenue
1.7M
-44.5%
3.1M
-57.6%
7.3M
-43.0%
12.8M
+138.0%
5.4M
Gross Profit
18.4M
+12.6%
16.4M
-37.2%
26.1M
+0.2%
26.0M
-22.9%
33.8M
Operating Expenses
77.0M
-18.9%
94.9M
-2.0%
96.8M
-16.5%
116.1M
+26.3%
91.9M
R&D
46.2M
-7.4%
49.9M
-0.4%
50.1M
-27.7%
69.4M
+29.9%
53.4M
SG&A
30.8M
-18.6%
37.8M
-17.8%
46.0M
+2.4%
45.0M
+28.5%
35.0M
Operating Income
-58548000
+25.4%
-78521000
-11.0%
-70752000
+21.4%
-90017000
-54.8%
-58163000
EBITDA
-46233000
+29.7%
-65722000
-16.6%
-56383000
+23.9%
-74104000
-88.3%
-39348000
Net Income
-46710000
+43.4%
-82587000
-2.3%
-80751000
+0.0%
-80755000
-33.9%
-60300000
EPS (Basic)
$-0.75
+46.0%
$-1.39
+1.4%
$-1.41
+2.8%
$-1.45
-31.8%
$-1.10
EPS (Diluted)
$-0.75
+46.0%
$-1.39
+1.4%
$-1.41
+2.8%
$-1.45
-31.8%
$-1.10
Shares (Diluted)
62.1M
+4.2%
59.6M
+4.3%
57.1M
+2.6%
55.6M
+1.4%
54.9M
Ginkgo Bioworks (DNA) โ€” Financials